Showing results filtered by:
32 Results
Dengue fever is an infectious disease carried by mosquitoes and caused by any of four related dengue viruses. This disease used to be called "break-bone" fever because it sometimes causes severe joint and muscle pain that feels like bones are breaking. Health experts have known about dengue fever for more than 200 years.Â
Last Reviewed: September 13, 2024
Cholera is an acute, diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae. An estimated 3-5 million cases and over 100,000 deaths occur each year around the world. The infection is often mild or without symptoms, but can sometimes be severe. Without treatment, death can occur within hours.
Last Reviewed: May 12, 2016
Information about the different types of Group A Streptococcal Infections from NIAID.
Last Reviewed: June 30, 2016
NIAID, in coordination with the HHS Biomedical Advanced Research and Development Authority (BARDA), supported preclinical and clinical research to develop several antibody-based therapeutics as anthrax antitoxins. One such product is Anthim, a human monoclonal antibody produced by Elusys Therapeutics, Inc.
Last Reviewed: November 19, 2024
Switching to an antiretroviral therapy (ART) regimen containing the drug dolutegravir was associated with a significant temporary increase in reservoirs of latent HIV, according to a new analysis from a study in Uganda. HIV reservoirs are cells where HIV lies dormant and cannot be reached by the immune system or ART. They are central to HIV’s persistence, preventing current treatments from clearing the virus from the body.
Published: March 14, 2024
NIAID-supported scientists are working to understand the pathology of dengue disease and to develop diagnostic tests for use in dengue-endemic countries.
Last Reviewed: October 3, 2011
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial to evaluate an investigational preventative vaccine for Epstein-Barr virus (EBV). EBV is the primary cause of infectious mononucleosis and is associated with certain cancers and autoimmune diseases. The Phase 1 study, which will be conducted at
Published: May 6, 2022
A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial. The vaccine, developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, could someday be an important tool to respond to Marburg virus
Published: January 30, 2023
A Phase 2 clinical trial will test the safety and efficacy of an experimental treatment for dengue, a viral disease transmitted by mosquitoes.
Published: February 11, 2025
Information about the various areas of malaria research supported by NIAID including the full cycle of malarial disease.
Last Reviewed: March 4, 2016
Allergy & Immunology Fellowship Program offers fellows the chance to work with faculty at the NIH Clinical Center, the Children's National Medical Center, and the Johns Hopkins Pediatric Allergy Clinic.
Last Reviewed: September 3, 2024
This blog is cross-posted from the National Institute on Drug Abuse and written by Dr. Nora Volkow, director of the National Institute on Drug Abuse (NIDA) and Dr. Jeanne Marrazzo, director of the National Institute of Allergy and Infectious Diseases. For complex reasons, HIV and substance use have been inextricably linked since the HIV epidemic began more than four decades ago. Consequently, it
Published: July 26, 2024
Immunologically complex emerging and reemerging viral diseases, including dengue and Zika Host immunologic correlates of enduring protection and disease Antigenic and genetic viral evolution Virus transmission dynamics
Last Reviewed: June 29, 2022
Information about various antimicrobial resistance threats including an overview of other pathogens of concern from NIAID.
Last Reviewed: February 11, 2020
Malaria, the fifth most deadly infectious disease, remains a public health priority. On April 25, World Malaria Day, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), joins with the global health community in reaffirming our commitment to ending this ancient parasitic disease. This year’s theme, “Accelerating the fight against
Published: April 25, 2024
Researchers seeking funding can access opportunities to further their own research, while NIAID and NIH grantees can find out about available resources outside of specific funding opportunities. Recent publications, active networks, and ways to connect with other researchers are also available.
Last Reviewed: October 31, 2024
NIH reports that an investigational COVID-19 vaccine by Janssen Pharmaceuticals appears to be safe and effective at preventing COVID-19 in adults.
Published: January 29, 2021
Explanation of two strategies under study for HIV viral eradication from NIAID.
Last Reviewed: March 26, 2019
Kirk Druey, M.D., is the Chief of the Lung and Vascular Inflammation Section (LVIS). The LVIS conducts broad and in-depth translational research that focuses on fundamental processes underlying allergic inflammation. Our research program includes studies aimed at mechanistic dissection of fungal associated-asthma and exploration of the pathogenesis of the rare vascular disorder resembling systemic anaphylaxis, a condition known as systemic capillary leak syndrome (SCLS, Clarkson disease)
Last Reviewed: July 12, 2022
Immune reconstitution after allogeneic Hematopoietic Stem Cell Transplantation Infections in transplant recipients
Last Reviewed: December 19, 2023
Results from a large clinical trial in the United States and South America indicate that AstraZeneca’s COVID-19 vaccine, AZD1222, is well-tolerated and protects against symptomatic COVID-19 disease, including severe disease or hospitalization.
Published: March 22, 2021
Bruce Swihart, Ph.D., is a Mathematical Statistician in the Biostatistics Research Branch at the National Institutes of Allergy and Infectious Diseases.
Last Reviewed: October 19, 2016
The Allergy & Immunology (A&I) Fellowship Program provides trainees with high-quality clinical and research skills prepares them to successfully pursue careers in academic medicine. Graduates are listed with their NIH mentor and where they went to work after graduation.
Last Reviewed: September 3, 2024
Dean D. Metcalfe, M.D., is the Chief of Mast Cell Biology Section. The mast cell is the focus of the Mast Cell Biology Section (MCBS) research effort. This multifunctional inflammatory cell is involved in both innate and acquired immunity and plays a central role in the induction of allergic inflammation.
Last Reviewed: May 19, 2022
We use a multidisciplinary approach encompassing virology, immunology, and epidemiology to investigate protection against and susceptibility to emerging viruses to inform safe and effective deployments of vaccines. Our primary expertise is in seroepidemiology, and our research focuses dengue, which we believe serves as a model pathogen for other complex, immune-evasive viruses.
Last Reviewed: February 23, 2023